PROCEPT BioRobotics Corporation (PRCT) Stock Analysis

Research · Sep 3, 2026

[PRCT] Procept BioRobotics Thesis 2026: Aquablation Volume Ramp Defines the Breakeven Path

Procept BioRobotics FY2025 revenue ~$308M (+31%) with ~9,800 annual AQUABEAM procedures across ~1,530 installed systems. Consumable revenue (~$163M) and service (~$35M) now ~63% of total, validating the recurring revenue model. Operating loss ~-$104M reflects commercial investment phase. FY2026 thesis: procedure volume inflection to 12,000-15,000 annually (from per-system utilization rising ~6.4 → ~8+ procedures/year as surgeon training matures); gross margin expansion toward 60% on consumable mix shift; breakeven at ~$500M revenue requires ~15,000 procedures/year at ~$2,800 average consumable; AQUABEAM's sexual function preservation advantage vs. TURP is primary adoption driver for sexually-active BPH patients.

Research · May 21, 2026

PRCT's 65% Q1 Margin Isn't Noise. It De-Risks the FY Guide.

Procept Biorobotics reported Q1 2026 gross margin of 65%, the highest in company history and a 440-basis-point sequential improvement, driven by pricing discipline and operational leverage. While the tape focused on commercial realignment headwinds (flat procedures, handpiece sales below 1:1 ratio), the margin inflection de-risks the full-year $390–410M revenue guide (27–33% growth) and 65% gross margin target. The stock sold off 5.7% on earnings day, suggesting the market has not yet priced the pricing power and margin expansion embedded in the trajectory.